Skip to main content

Table 2 Carriage prevalence per 100 children, overall and by vaccine-type and non-vaccine type, in 2015

From: Changes in pneumococcal carriage prevalence and factors associated with carriage in Norwegian children, four years after introduction of PCV13

Variable

Number of carriers per subgroup

Prevalence carriage, per 100 children [95%CI]

Prevalence PCV7a carriage number; prevalence per 100 children [95%CI]

Prevalence PCV13–7b carriage number; prevalence per 100 children [95%CI]

Prevalence NVTc carriage number; prevalence per 100 children [95%CI]

Total

431

48.1 [43.7–52.5]

12; 1.3 [0.7–2.4]

13;1.5 [0.8–2.6]

412; 46.0 [41.5–50.5]

Age in months

431 included

    

< 24 months

84

60.4 [52.2–68.1]

0; 0 [NA]

1; 0.72 [0.09–5.4]

84; 60.4 [52.2–68.1]

24–35 months

94

56.0 [48.1–63.6]

2; 1.2 [0.28–5.0]

1; 0.60 [0.08–4.4]

91; 54.2 [46.0–62.1]

36–47 months

105

53.9 [46.0–61.5]

4; 2.0 [0.61–6.7]

6; 3.0 [1.5–6.1]

98;50.3 [42.8–57.7]

48–59 months

89

42.8 [35.5–50.5]

2; 0.96 [0.25–3.6]

5; 2.4 [0.85–6.6]

84; 40.4 [33.0–48.3]

> = 60 months

59

31.7 [24.6–39.8]

4; 2.2 [0.83–5.5]

0; 0 [NA]

55; 29.6 [22.8–37.4]

Vaccinated by type

428 included

    

PCV7

20

34.5 [22.9–48.3]

1; 1.7 [0.22–12.1]

0; 0 [NA]

19; 32.8 [21.1–47.0]

PCV7+13

52

30.1 [23.0–38.3]

2; 1.2 [0.28–4.7]

1; 0.58 [0.08–4.1]

49; 28.3 [21.7–36.9]

PCV13

354

54.5 [50.0–58.9]

8; 1.2 [0.54–2.8]

12; 1.9 [0.98–3.5]

340; 52.3 [47.7–56.9]

Unvaccinated

2

40.0 [11.1–78.0]

1; 20.0 [6.7–46.7]

0; 0 [NA]

1; 20.0 [6.7–46.7]

Having used antimicrobials the past 3 months

428 included

    

Yes

28

40.6 [30.9–51.1]

0; 0 [NA]

0; 0 [NA]

28; 40.6 [30.9–51.1]

No

400

48.5 [44.0–53.1]

12; 1.5 [0.80–2.6]

12; 1.5 [0.78–2.7]

382; 46.4 [41.7–51.1]

  1. acarriage of serotypes covered by the 7-valent pneumococcal conjugate vaccine
  2. bcarriage of serotypes covered by the 13-valent pneumococcal conjugate vaccine but not by the 7-valent vaccine
  3. ccarriage of serotypes not covered by the 13-valent pneumococcal conjugate vaccine
  4. NA not applicable (the 95% could not be determined because  no children in this category carried these types)